Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | TTPA | P49638 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165364 | 0.97 | CA12 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL256549 | 0.97 | CA12 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL257159 | 0.90 | PTGS2 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL166762 | 0.90 | PTGS2 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL257131 | 0.90 | PTGS2 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL13396531 | 0.89 | CA12 (0.40) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL13396347 | 0.85 | CA12 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL13396503 | 0.84 | CA12 (0.42) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL14095438 | 0.84 | SLC7A5 (0.44) | — | |
| SCHEMBL13397320 | 0.84 | SLC7A5 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085528-B2 | Nitric oxide amino acid ester compound, composition for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085528-B2 | Nitric oxide amino acid ester compound, composition for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-7807716-B2 | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-7807716-B2 | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| WO-2010034118-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-03-25 | — | — | US | disclosed |
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | NOS1, NOS2, NOS3 | PTGS2 305/4885CA12 3019/4885CA1 1816/4885 |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | PTGS2 68/4885CA12 1950/4885CA1 780/4885 |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | NOS1, NOS2, NOS3 | PTGS2 852/4885CA12 3908/4885CA1 1630/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | PTGS2 68/4885CA12 1950/4885CA1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.